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The main defence of the patent system is based on the argument that it acts as an incentive for investing in research and development. In order to benefit from patent protection, manufacturers need to demonstrate that they have contributed sufficiently to the drug innovation process. In the field of HIV/AIDS, the public sector -principally universities and large publicly funded government research organisations -have contributed significantly, and sometimes entirely, to the research and development of many key ARVs. Abacavir, didanosine, stavudine, zalcitabine, zidovudine and the concept of protease inhibition have all received substantial public funding in their discovery and development. 4, 5 Public interest and patient groups have successfully challenged the legitimacy of a number of ARV patents, based on the fact that patent holders did nothing significantly inventive to deserve a monopoly. In Thailand, Bristol-Myers Squibb's patent for didanosine was overturned on the grounds that the patent holder manipulated the details of the patent claim, and the fact that most of the research and development was done by the US National Institutes of Health. 6 In India and Thailand, civil society groups managed to successfully block a patent application by GlaxoSmithKline for the combination zidovudine+lamivudine on the grounds that simply combining two known and already patented drugs was not sufficiently inventive to warrant an extended monopoly. 7 In South Africa, the purchasing of generic stavudine was made possible because of a challenge to the licensing agreement between Bristol-Myers Squibb and the patent owner, Yale University. 8 Each of these initiatives has led to significant cost savings, as is clearly demonstrated by the precipitate fall in the price of branded stavudine in South Africa, from more than US$1 539 per adult patient/ year in 2000 to less than US$77 in 2008. Generic versions cost even less.
Tenofovir disoproxil fumarate (TDF) is a desirable ARV because it is regarded as safe, requires relatively limited toxicity monitoring, and is administered once daily. At the end of January 2008, the US Patent and Trademark Office revoked four key patents held by Gilead Sciences for TDF. This followed a challenge by a US public interest organisation (the Public Patent Foundation) that showed that TDF was already a known substance by the time Gilead applied for the patents. 9 (Much of the research work was done by the Academy of Sciences of the Czech Republic and the Catholic University in Leuven, Belgium. Emtricitabine, which is partnered with TDF in a once-a-day dosage form, Truvada, was similarly discovered by public researchers at Emory University.) Similar patent challenges have been filed by civil society groups in India, and Thailand is expected to follow suit.
Patent challenges have been raised in part because of the unreasonably high cost and significant variation in pricing of TDF. For example, Brazil, South Africa and Thailand have very similar gross domestic products, but the price of TDF
in Brazil is three times that in Thailand and six times that in South Africa (Table I ).
In India, the TDF patent has not yet been granted by the Indian Patent Office, but Gilead has managed to limit generic competition by entering into voluntary licence agreements with the majority of Indian generic manufacturers capable of producing the product or its active pharmaceutical ingredient (including Matrix, Ranbaxy, Hetero, Aurobindo and Emcure). These voluntary licences impose restrictions so that, for example, manufacturers cannot export to middle-income countries such as South Africa and Brazil, preventing the option of sourcing alternative price options and limiting access to alternative supplies of drug in the event of shortage. The TDF market for Africa has been awarded to Aspen Pharmacare (Gilead has not patented TDF in South Africa, but has relied on the licensing agreement with Aspen to manage the market). 11 However, as Gilead itself will not market TDF (or the combination of TDF and emtricitabine) in these countries, the overall result is that TDF remains a monopoly (single-source) product.
If Gilead's patents are rejected by the Indian Patent Office, the voluntary licence agreements signed between Gilead and Indian manufacturers will probably become void. This means that generic manufacturers will be able to freely manufacture and export generic versions of tenofovir without restrictions.
The place of TDF in the management of HIV/AIDS has been variably described in treatment guidelines; this variability is directly influenced by considerations of price when applied to the developing world. For example, the United States Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents lists TDF and emtricitabine among its firstline 'preferred' choices. 12 The 6th edition of Aid for AIDS Guidelines (used widely in South Africa's private sector), while noting that TDF was not yet registered in the country in 2007, stated that '… [i]ts best current role is in initial therapy, combined with either lamivudine or emtricitabine' . 13 In March 2007, the World Health Organization (WHO) included TDF in the 15th Model Essential Medicines List. 14 In May 2007, a WHO Working Group recommended that TDF be included (with lamivudine, considered equivalent to emtricitabine) as the preferred non-nucleoside/nucleotide reverse transcriptase (NRTI) background option for secondline ARV therapy in developing countries using thymidinebased first-line regimens. A number of countries in southern Africa have either moved to using TDF as part of first-line regimens (Lesotho) or are considering such a move (Zambia). TDF is increasingly needed in all programmes using stavudine as first-line therapy for the growing number of patients who develop toxicity to stavudine (lipoatrophy, peripheral neuropathy, symptomatic hyperlactataemia and lactic acidosis). One study found that 21% of patients starting on a d4T-based regimen required a switch to an alternative ARV within 3 years because of toxicity. 15 Cost is a major factor for considering a move to providing TDF as a first-line ART option. A recent cost-effectiveness analysis estimated that, for TDF to replace d4T at a neutral cost, the price of TDF would need to fall to US$72 per person/year -a third of the current price (personal communication -Sydney Rosen). This is not unrealistic. Experts involved in ARV price negotiations and forecasting are anticipating significant reductions for TDF. It is expected that TDF is likely to fall to around US$120 per person/year in the next 12 -18 months; in the long term, it is certainly possible that prices could fall to well below $100 (personal communication -Aaron Pattillo, Clinton Foundation).
However, there are two major obstacles to South Africa being able to access these prices: the ARV tender process for 2008, and the medicines registration process. tender will allow for its procurement. It is also not clear whether a generic manufacturer, which holds neither patent nor agreement with the patent holder, will be able to enter the process, even if that generic production is entirely consistent with intellectual property law.
Two other clauses in the 2004 request for proposals relate to registration and are standard for all medicine tenders:
3.1 Bidders offering medicines which require registration in terms of the Medicines and Related Substances Act, (Act 101 of 1965 as amended), must be in possession of valid registration certificates, issued in terms of the said Act at the closing date and time of the request for proposal/ quotation, and must comply with the conditions under which the medicines have been registered. Copies of registration certificates for drugs offered must be supplied with the bid document at the closing date and time of the request for proposal/quotation.
Bidders offering medicines must supply proof of positive GMP status with the Medicines Control
Council which must be submitted with the bid document at the closing date and time of the request for proposal/quotation. ARV scale-up in the developing world was made possible because of a simple, affordable first-line regimen using public health principles. As HIV treatment programmes mature, the need for newer medicines to overcome toxicity and resistance is becoming increasingly urgent. Faced with rising treatment costs, a number of developing countries have taken strong action against the monopolies on key ARV patents, resulting in significant cost savings.
For South Africa, broader access to TDF has the potential to simplify treatment by offering a more favourable sideeffect profile, an issue that is particularly important in facilitating the provision of care at the primary care level.
Further potential for simplification is presented by the use of TDF in the once-a-day combination of tenofovir/ emtricitabine/efavirenz (and potentially tenofovir/ lamivudine/nevirapine).
Internationally, the cost of TDF is set to fall significantly in the coming months. The price that South Africa will pay will depend on whether the tender process will allow for the inclusion of new, unpatented medicines and how quickly these new products can be registered. Neither of these issues is immutable: they are simple matters of policy choice.
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